Sustainable living. learning. researching

Medical University of Graz

Publikationen

2017

Switching or restarting of tumour necrosis factor-a inhibitors after interruption under daily-life conditions: efficacy report from the Austrian Psoriasis Registry (PsoRA).Wolf, P; Weger, W; Richter, L; Mlynek A; Sator, P; Saxinger, W; Ratzinger, G; Kölli, C; Painsi, C; Bangert, C; Tatarski, R; Schütz-Bergmayr, M; Ponholzer, P; Trautinger, F; Strohal, R; Müllegger, R; Inzinger, M; Lichem, R; Salmhofer, W; Quehenberger, F. Presented at Psoriasis Gene to Clinic, 8th International Congress. The Queen Elizabeth II Conference Centre, London, U.K., 30th November – 2nd December 2017. Br J Dermatol 2017;177, ppe235–e307

2015

Psoriasis Area and Severity Index 75 rate of classical inpatient dithranol therapy under daily life conditions. Painsi, C; Patscheider, M; Inzinger, M; Huegel, R; Lange-Asschenfeldt, B; Quehenberger, F; Wolf, P; Br J Dermatol 2015; 173:815-817

Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey. Painsi, C; Patscheider, M; Inzinger, M; Lange-Asschenfeldt, B; Quehenberger, F; Wolf, P; J Dtsch Dermatol Ges 2015; 13:1156-1163

2014

Short- to intermediate-term follow-up in patients treated with the combination of 311-nm ultraviolet B phototherapy and biological agents. Inzinger, M; Legat, FJ; Hofer, A; Weger, W; Gruber-Wackernagel, A; Salmhofer, W; Wolf, P; Br J Dermatol 2014; 171(4): 915-917

Drug adherence of tumor necrosis factor-α-inhibitors in the treatment of plaque psoriasis under daily life conditions in Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstracts of the 23rd Congress of the European Academy of Dermatology and Venereology; OCT 08-12, 2014; Amsterdam, Netherlands

Intermediate to long-term efficacy of tumor necrosis factor (TNF)-α inhibitors in the treatment of plaque psoriasis under daily life conditions in Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstracts of the 23rd Congress of the European Academy of Dermatology and Venereology; OCT 08-12, 2014; Amsterdam, Netherlands

Survival to adalimumab, etanercept, infliximab and ustekinumab in the treatment of plaque psoriasis under daily life conditions: report from Psoriasis Registry Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria

Reported comorbitities in patients with psoriasis who are enrolled in the Psoriasis Registry Austria (PsoRA). Inzinger, M; Weger, W; Wippel-Slupetzky, K; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria

Drug survival of ustekinumab in the treatment of psoriasis under daily life condidions: report from Psoriasis Registry Austria. Weger, W; Inzinger, M; Wippel-Slupetzky, K; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria

2013

Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. Inzinger, M; Weger, W; Heschl, B; Salmhofer, W; Quehenberger, F; Wolf, P; J Eur Acad Dermatol Venereol 2013; 27(7): 861-866

PASI-Reduktion bei Cignolin-Therapie. Painsi, C; Patscheider, M; Inzinger, M; Quehenberger, F; Lange-Asschenfeldt, B; Wolf, P; Abstractband 2013; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 22-24, 2013; Vienna, Austria

Patientenzufriedenheit und Wirksamkeit bei stationärer Cignolin-Therapie. Painsi, C; Patscheider, M; Inzinger, M; Quehenberger, F; Lange-Asschenfeldt, B; Wolf, P; Abstractband 2013; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 22-24, 2013; Vienna, Austria

2012

Intermediate to long-term efficacy and safety of etanercept: report from the psoriasis registry Austria. Inzinger, M; Roschatt, I; Weger, W; Salmhofer, W; Wolf, P; J Invest Dermatol 2012; 132: S60-S60. 42nd Annual Meeting of the European Society for Dermatological Research (ESDR); SEP 07-10, 2012; Venice, Italy

  • VMC Moodle
  • Forschungportal
  • MEDonline
  • Library